20 Contract Development and Manufacturing Organizations (CDMOs) OF 2025

Shots:

CDMOs have become central to the modern biopharmaceutical ecosystem, helping companies accelerate development timelines, navigate rising technical complexity, and bring innovative therapies to market with greater efficiency

The global CDMO market continues to post strong double-digit growth and is projected to reach nearly $255B by 2025. This momentum is driven by increased outsourcing, the surge in complex biologics, and the growing burden of chronic diseases that require advanced therapeutic solutions

Amid evolving regulatory expectations and accelerating digital transformation, leading CDMOs such as AbbVie Contract Manufacturing, Patheon (Thermo Fisher), and Lonza are setting new benchmarks for capability and reliability

20. Syngene International

Founded Year: 1993

Total Employees: 6,500

Headquarters: Karnataka, India

Ticker: SYNGENE

Stock Exchange: NSE

Syngene provides fully integrated discovery, development, and commercial manufacturing services to the pharma, biotech, nutrition, and specialty chemicals sectors. Its end-to-end model supports programs from early research through scale-up to offer a seamless path from concept to market.

The company’s scientific depth spans multiple therapeutic modalities, including small molecules, biologics, peptides, and antibody-drug conjugates (ADCs). With capabilities spanning discovery, development, and GMP manufacturing, Syngene helps companies support complex R&D pipelines

In Jun’24, Syngene expanded its offering with the launch of a new platform designed to enable rapid, enhanced protein production, further strengthening its ability to support accelerated biologics development

19. Siegfried Holdings

Founded Year: 1873

Total Employees: 3,900

Headquarters: Aargau, Switzerland

Ticker: SFZN

Stock Exchange: SWX

Siegfried is a global Swiss CDMO that provides development and manufacturing services for both active pharmaceutical ingredients (APIs) and finished dosage forms. The company supports a broad range of pharmaceutical and biotechnology partners, offering expertise across the full life cycle of small-molecule products

With end-to-end capabilities, Siegfried delivers a seamless pathway from early development through commercial production. Through its integrated approach, the company offers a comprehensive suite of services spanning process development and optimization to registration, production, packaging, and logistics

In July 2024, Siegfried expanded its footprint by signing an agreement with Curia Global to acquire a CDMO site in Wisconsin, strengthening its drug substance (DS) services and enhancing capacity within the US market

18. Bachem Holding

Founded Year: 1971

Total Employees: 2,300

Headquarters: Basel-Landschaft, Switzerland

Ticker: BANB

Stock Exchange: SWX

Bachem is a specialized CDMO dedicated to the development and manufacturing of peptides and oligonucleotides. The company supports global pharma and biotech clients with quality APIs and tailored custom synthesis solutions

Bachem offers services across all stages of development, backed by flexible manufacturing capacities that accommodate both small-scale and large-scale supply needs. This breadth of capability enables consistent support from early research through commercial production

In 2024, the company reported a 4.8% increase in group sales (CHF), reflecting steady demand for its peptide and oligonucleotide offerings

17. Samsung Biologics

Founded Year: 2011

Total Employees: 5,000

Headquarters: Incheon, Republic of Korea

Ticker: 207940

Stock Exchange: KRX

Samsung Biologics is a fully integrated global CDMO with a focus on monoclonal antibodies, bispecific antibodies, antibody–drug conjugates (ADCs), and mRNA vaccines. The company supports clients across the biologics value chain with scalable development and manufacturing capabilities

It’s service portfolio spans late discovery through commercial production, including cell line development, DS manufacturing, and aseptic fill-finish operations with an end-to-end framework enabling streamlined progression from early development to market supply

In Nov’24, Samsung Biologics entered a manufacturing agreement with a European pharmaceutical company, further expanding its global collaboration footprint

16. Laurus Labs

Founded Year: 2005

Total Employees: 6,200

Headquarters: Telangana, India

Ticker: LAURUSLABS

Stock Exchange: NSE

Laurus is an India-based multinational pharmaceutical and biotechnology company with a diversified focus across APIs, generic formulations, custom synthesis, biotechnology, veterinary APIs, and agrochemicals

Its operations span global markets, supported by capabilities in small-molecule APIs, finished dosage forms, and biologics

In Dec’24, Laurus Bio (Laurus Labs) signed a definitive agreement to secure approximately $14M in equity investment from Eight Roads Ventures and F-Prime Capital. This investment aims to strengthen Laurus Bio’s position in the biologics and synthetic biology space while supporting long-term growth initiatives

15. AGC Biologics

Founded Year: 2018

Total Employees: 53,700

Headquarters: Tokyo, Japan

Ticker: 5201

Stock Exchange: TYO

AGC Biologics, part of the larger AGC conglomerate, is a global CDMO specializing in the development and manufacturing of protein-based biologics and advanced therapies

The company supports a broad range of partners with end-to-end capabilities designed to streamline biologics and cell and gene therapy programs

In Dec’24, AGC Biologics introduced its CMC Jumpstart program, offering early-stage assessments for gene-of-interest (GOI) candidates using viral vector platforms. This initiative aims to accelerate development timelines and provide clearer pathways for advancing emerging gene therapy assets

14. Charles River Laboratories

Founded Year: 1947

Total Employees: 19,400

Headquarters: Massachusetts, United States

Ticker: CRL

Stock Exchange: NYSE

Charles River Laboratories is a US-based pharmaceutical and biotechnology CRO and CDMO providing comprehensive support across early research, preclinical testing, and advanced manufacturing

The company delivers a broad range of preclinical and clinical laboratory services essential for the development of new drugs, vaccines, and medical devices, and offers CDMO capabilities for cell and gene therapies

In Jun’24, Charles River and Captain T Cell announced a collaboration focused on plasmid DNA and viral vector manufacturing to advance gene-modified cell therapy programs, strengthening the company’s position in the growing CGT development ecosystem

13. Aurigene Pharmaceutical Services

Founded Year: 2002

Total Employees: 27,800

Headquarters: Telangana, India

Ticker: DRREDDY

Stock Exchange: NSE

Aurigene Pharmaceutical Services, a subsidiary of Aurigene Discovery Technologies and part of Dr. Reddy’s Laboratories, provides end-to-end discovery-to-commercial services across both small molecules and biologics

Aurigene offers biotherapeutics research, API and intermediate development (including highly potent molecules), formulation development, and GMP manufacturing for clinical and commercial supply

In Jul’24, Aurigene began offering cell-therapy discovery services to Edity Therapeutics, following Dr. Reddy’s strategic investment in the Israel-based biotech, further expanding its presence in advanced therapy development

12. Eurofins

Founded Year: 1987

Total Employees: 65,000

Headquarters: Val Fleuri, Luxembourg

Ticker: ERF

Stock Exchange: EPA

Eurofins Scientific SE is a global leader in laboratory testing and bio-analysis, operating a network of more than 950 laboratories across over 60 countries, supporting a wide range of scientific and regulatory needs for biopharma and adjacent industries

Beyond its core biopharma offerings, which include CRO and CDMO services, development support, GMP testing, and central laboratory operations, Eurofins also provides testing services across food and feed, environmental and agroscience, clinical diagnostics and IVD, as well as consumer and technology product testing

In Sep’24, Eurofins strengthened its U.S. BioPharma Product Testing capabilities with the acquisition of Infinity Laboratories, further enhancing its GMP testing and analytical services portfolio

11. WuXi Biologics

Founded Year: 2010

Total Employees: 12,600

Headquarters: Jiangsu, China

Ticker: 2269

Stock Exchange: HKG

WuXi Biologics is a leading global CDMO focused exclusively on biologics development and manufacturing, supporting programs from early discovery through commercial production. The company’s end-to-end model provides a streamlined pathway for advancing complex biologics across multiple modalities

Its capabilities span cell line and process development, DS and drug product (DP) manufacturing, aseptic fill–finish, and specialized platforms for monoclonal antibodies, bispecifics, ADCs, fusion proteins, and other biologic formats

In 2024, WuXi Biologics supported 66 Phase III studies and 21 non-COVID commercial projects, underscoring the continued expansion of its manufacturing pipeline and the strong confidence placed in its global platforms

10. West Pharmaceutical Services

Founded Year: 1923

Total Employees: 10,600

Headquarters: Pennsylvania, United States

Ticker: WST

Stock Exchange: NYSE

West Pharmaceutical Services is a global leader in the design and manufacture of advanced containment and delivery systems for injectable medicines. The company supports biopharma partners with a broad portfolio of solutions designed to ensure product safety, compatibility, and efficient delivery

Its service offerings span primary packaging components, self-injection and wearable delivery devices, contract manufacturing, and a suite of analytical and testing services, including extractables and leachables, container-closure integrity, particulate analysis, and regulatory support

In August 2024, West completed an $80M capacity-expansion project at its contract manufacturing facility in Michigan, strengthening its ability to meet growing global demand for high-quality injectable drug delivery components

9. Divi’s Laboratories

Founded Year: 1990

Total Employees: 10,500

Headquarters: Telangana, India

Ticker: DIVISLAB

Stock Exchange: NSE

Divi’s Laboratories specializes in generic APIs, custom synthesis, and nutraceuticals. With state-of-the-art facilities, strong R&D capabilities, and advanced manufacturing technologies, Divi’s continues to drive innovation and strengthen its position as a key contributor to the global pharmaceutical supply chain

Its core portfolio includes large-scale generic APIs, custom synthesis services for innovator companies, and a broad nutraceutical offering encompassing carotenoids, vitamins, and other specialty ingredients. This diversified capability base supports both mainstream and niche market needs

The upcoming Kakinada facility, a new capacity addition, are expected to come online in H2’25. These expansions will further enhance Divi’s manufacturing footprint and support long-term growth across its API and nutraceutical businesses

8. Fujifilm Diosynth Biotechnologies (Fujifilm Holdings)

Founded Year: 1923

Total Employees: 72,600

Headquarters: Tokyo, Japan

Ticker: 4901

Stock Exchange: TYO

FUJIFILM Diosynth, a subsidiary of Fujifilm Holdings, is a global CDMO specializing in the development and manufacturing of biologics, vaccines, advanced therapies, and oncolytic viruses

Its offerings span the full biologics development continuum, including its ApolloX cell-line development platform, mammalian and microbial DS manufacturing, viral-vector and cell-therapy production, analytical development, and comprehensive DP and fill-finish capabilities

In Nov’24, FUJIFILM Diosynth Biotechnologies entered a multi-year manufacturing supply agreement with TG Therapeutics for Briumvi (ublitiximab-xiiy), further expanding its commercial manufacturing portfolio and strengthening its partnerships in the immunology and neurology landscape

7. WuXi AppTec

Founded Year: 2000

Total Employees: 37,800

Headquarters: Shanghai, China

Ticker: 603259

Stock Exchange: SHA

WuXi provides an extensive portfolio of R&D, drug testing, and manufacturing services across Asia, Europe, and North America. Its integrated model spans chemistry, drug CRDMO services, biology discovery, preclinical and clinical research support, as well as cell and gene therapy development through its CTDMO platform

The company’s CRDMO capabilities cover small molecules, oligonucleotides, and peptides, offering seamless progression from discovery to commercial manufacturing. As a CTDMO, WuXi AppTec delivers solutions for advanced biopharmaceuticals, including gene and cell therapies, enabling partners to accelerate development across next-generation modalities

In Jan’24, WuXi significantly expanded its peptide manufacturing footprint by tripling capacity, adding two new peptide plants, one at its Changzhou site and another at the newly launched Taixing API facility in China. This expansion strengthens its global supply capabilities and supports growing demand for complex peptide therapeutics

6. Sun Pharma

Founded Year: 1983

Total Employees: 43,000

Headquarters: Maharashtra, India

Ticker: SUNPHARMA

Stock Exchange: NSE

Sun Pharmaceutical Industries, widely recognized as India’s largest pharmaceutical company and a leading global specialty generics player, also maintains a strong presence in the CRAMS/CDMO space. The company supports innovator partners with a comprehensive suite of development and manufacturing services

Sun Pharma’s end-to-end CRAMS/CDMO capabilities include route design, process and analytical development, GMP and non-GMP scale-up, kilo-lab and pilot plant manufacturing, commercial API production, impurity and stability studies, and full CMC and regulatory support. This integrated model enables seamless progression from early development to market-ready supply

In Jul’24, Sun Pharma and Samsung Biologics announced a strategic manufacturing agreement for Tildrakizumab, further strengthening Sun Pharma’s collaborations in biologics and expanding its footprint in global specialty therapeutics

5. Lonza

Founded Year: 1897

Total Employees: 19,300

Headquarters: Basel-Stadt, Switzerland

Ticker: LONN

Stock Exchange: SWX

Lonza is a global CDMO leader with a broad portfolio spanning integrated biologics, small-molecule synthesis, and advanced modalities including cell and gene therapies. With operations across more than 30 sites worldwide, the company supports biopharma partners at every stage of the development and manufacturing lifecycle

Lonza’s capabilities include cell-line development, formulation, process scale-up, GMP DS and DP manufacturing, viral-vector and cell-therapy production, and comprehensive fill-finish solutions. This end-to-end framework enables reliable progression from early development through commercial supply

In Sep’24, Lonza entered into a long-term commercial supply agreement with Vertex for Casgevy (exagamglogene autotemcel), reinforcing its role as a key manufacturing partner in the rapidly expanding gene-editing and cell-therapy landscape

4. MilliporeSigma

Founded Year: 1954

Total Employees: 62,300

Headquarters: Hesse, Germany

Ticker: MRK

Stock Exchange: ETR

MilliporeSigma a subsidiary of Merck KGaA, operates a global CDMO network specializing in complex biologics, high-potency APIs (HPAPIs), antibody–drug conjugates (ADCs), and viral/vector-based modalities. Its diversified capabilities position the company as a key partner for advancing next-generation therapeutics across multiple technology platforms

The company’s service portfolio spans process development, analytical testing, GMP DS and DP manufacturing, HPAPI production, conjugation services, and full viral/vector development and manufacturing through its BioReliance offering. This integrated framework enables seamless progression from early development to commercial supply for complex and high-potency molecules

In October 2024, MilliporeSigma announced a $76M expansion of its ADC manufacturing capabilities at the Bioconjugation Center of Excellence in St. Louis, Missouri, enhancing capacity to support the growing demand for clinical and commercial ADC programs

3. Pfizer Centreone (Pfizer)

Founded Year: 2015

Total Employees: 81,000

Headquarters: New York, United States

Ticker: PFE

Stock Exchange: NYSE

Pfizer CentreOne serves as Pfizer’s embedded global CDMO business, leveraging more than 35 manufacturing sites across six continents to deliver high-quality development, scale-up, and commercial manufacturing solutions. Its work is supported by Pfizer’s extensive regulatory, technical, and quality infrastructure, offering partners a reliable path from early development to global supply

The company’s core services include custom small-molecule API synthesis, biologics and sterile injectable fill-finish, oral solid dose manufacturing, and specialized capabilities such as ADC payload and linker production, analytical development, tech transfer, and lifecycle management

In 2024, Pfizer CentreOne expanded its development services group to engage earlier in the drug development lifecycle, aiming to enhance program success rates and better support the transition from early-phase development to commercial scale

2. Patheon

Founded Year: 1956

Total Employees: 125,000

Headquarters: Massachusetts, United States

Ticker: TMO

Stock Exchange: NYSE

Thermo Fisher Scientific expanded its pharma services footprint with the acquisition of leading CDMO Patheon in 2017 for approximately $7.2B, establishing a fully integrated platform that spans drug development, clinical trial logistics, and large-scale commercial manufacturing

Patheon delivers end-to-end solutions across every phase of development, including small-molecule and biologics APIs, viral vectors, cGMP plasmids, formulation development, clinical trial services, global logistics, and commercial manufacturing and packaging. This comprehensive capability set enables seamless progression from early research through market launch

In 2024, Thermo Fisher Scientific introduced its Accelerator Drug Development platform, offering unified CDMO and CRO support in a 360° model. This initiative strengthens its ability to provide fully integrated development and manufacturing services across the entire pharmaceutical lifecycle

1. Abbvie Contract Manufacturing

Founded Year: 2013

Total Employees: 55,000

Headquarters: Illinois, United States

Ticker: ABBV

Stock Exchange: NYSE

AbbVie Contract Manufacturing serves as the company’s dedicated CDMO platform, giving partners access to ~12 global GMP facilities and AbbVie’s deep expertise across biologics, small molecules, HPAPIs, microbial fermentation, and complex drug-product manufacturing

The organization delivers integrated, end-to-end solutions across the development lifecycle, including biologics development and DS manufacturing (mAbs, bispecifics, fusion proteins, ADC conjugation), custom small-molecule and HPAPI synthesis, aseptic fill–finish, oral/topical/ophthalmic formulations, analytical services, and advanced technologies such as hot-melt extrusion (HME)

In Jan’24, AbbVie advanced its global capacity footprint by breaking ground on a $223M expansion of its Singapore facility, strengthening capabilities to support next-generation biologics and high-complexity therapeutics

Source link